These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ovine corticotropin-releasing factor and vasopressin: antibody-quenching studies on hypothalamic extracts of normal and Brattleboro rats.
    Author: Linton EA, Gillies GE, Lowry PJ.
    Journal: Endocrinology; 1983 Nov; 113(5):1878-83. PubMed ID: 6605243.
    Abstract:
    Stalk median eminence (SME) extracts were preincubated with antibodies to ovine corticotropin-releasing factor (oCRF) and/or vasopressin, and the resulting CRF bioactivity tested with the isolated anterior pituitary cell column bioassay. The ACTH-releasing ability of Wistar rat SME was reduced by 60% with vasopressin antiserum, by 53% with oCRF antiserum, and by 81% after incubation with both antisera simultaneously. SME-stimulated LH release was unaffected by these antisera, which were all used at a dilution of 1:1000. The ACTH-releasing activity of SME could not be completely abolished by increasing the oCRF antibody concentration, or, in the case of ovine SME, by decreasing the tissue concentration preincubated with oCRF antibodies. With Brattleboro SME (which contains no endogenous vasopressin) ACTH-releasing activity was reduced by 37%, 51%, and 57% with anti-oCRF at dilutions of 1:5000, 1:1000, and 1:500, respectively, but could not be reduced further by more concentrated antisera. We conclude, therefore, that the CRF bioactivity of rat SME is probably not due solely to an oCRF-like peptide, but that other substances, one being vasopressin, contribute to its ACTH-releasing ability.
    [Abstract] [Full Text] [Related] [New Search]